CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parekh, T. V.
Right arrow Articles by Newman, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parekh, T. V.
Right arrow Articles by Newman, M. J.

Cell Growth & Differentiation, Vol 9, Issue 5 423-433, Copyright © 1998 by American Association of Cancer Research


ARTICLES

Type V collagen is an epithelial cell cycle inhibitor that is induced by and mimics the effects of transforming growth factor beta1

TV Parekh, XW Wang, DM Makri-Werzen, DS Greenspan and MJ Newman
Preclinical Oncology Discovery, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA.

The regulation of epithelial cell cycle progression by extracellular matrix proteins was investigated in mink lung epithelial cells (Mv1Lu cells) and primary human keratinocytes. Exogenous type V collagen was able to mimic all of the inhibitory effects of type 1 transforming growth factor beta (TGF-beta1). No significant inhibitory effect was observed with collagen types I, III, and IV; laminin; or fibronectin. The type V collagen used was not contaminated with TGF-betas. TGF-beta1 increased the rate of type V collagen protein secretion in Mv1Lu cells, which occurred coincident with DNA synthesis inhibition. Both TGF-beta1 and type V collagen inhibited retinoblastoma protein phosphorylation and the expression of cyclin-dependent kinase (cdk) 4 and cdk2, but not p27Kip expression. Mv1Lu cells constitutively expressing the SV40 T antigen or cdk4 were resistant to the inhibitory effects of both TGF-beta1 and type V collagen. Our results demonstrate that type V collagen is a novel and specific epithelial cell cycle inhibitor and suggest that it may act as an autocrine mediator of the inhibitory effects of TGF-beta1.


This article has been cited by other articles:


Home page
FASEB J.Home page
C. ALEXAKIS, A. GUETTOUFI, P. MESTRIES, C. STRUP, D. MATHE, C. BARBAUD, D. BARRITAULT, J.-P. CARUELLE, and P. KERN
Heparan mimetic regulates collagen expression and TGF-{beta}1 distribution in gamma-irradiated human intestinal smooth muscle cells
FASEB J, July 1, 2001; 15(9): 1546 - 1554.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
W. F. Vogel, A. Aszodi, F. Alves, and T. Pawson
Discoidin Domain Receptor 1 Tyrosine Kinase Has an Essential Role in Mammary Gland Development
Mol. Cell. Biol., April 15, 2001; 21(8): 2906 - 2917.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1998 by the American Association of Cancer Research.